219 related articles for article (PubMed ID: 29548318)
21. Effectiveness of the Polish program for the treatment of severe allergic asthma with omalizumab: a single-center experience.
Kupryś-Lipińska I; Majak P; Molinska J; Kuna P
BMC Pulm Med; 2016 Apr; 16(1):61. PubMed ID: 27117315
[TBL] [Abstract][Full Text] [Related]
22. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
[TBL] [Abstract][Full Text] [Related]
23. Inhaled Corticosteroid-Containing Treatment Escalation and Outcomes for Patients with Asthma in a U.S. Health Care Organization.
Bengtson LGS; Yu Y; Wang W; Cao F; Hulbert EM; Wolbeck R; Elliott CA; Buikema AR
J Manag Care Spec Pharm; 2017 Nov; 23(11):1149-1159. PubMed ID: 29083972
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness and safety of omalizumab in severe, persistent IgE-mediated asthma in pediatric and adult patients: a real-world observational study in Egyptian population.
Tarraf HN; Masoud HH; Zidan M; Wahba B
J Asthma; 2020 Feb; 57(2):160-166. PubMed ID: 30592242
[No Abstract] [Full Text] [Related]
25. [Analysis of asthma control and quality of life in severe allergic asthmatics under treatment with anti-IgE, omalizumab].
Pacheco-Galván A; Hinojosa-Macías M; Hurtado-Barbudo B; González-Cervera J; Sueiro-Bendito A
Med Clin (Barc); 2009 Oct; 133(12):460-3. PubMed ID: 19775710
[TBL] [Abstract][Full Text] [Related]
26. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal.
Burch J; Griffin S; McKenna C; Walker S; Paton J; Wright K; Woolacott N
Pharmacoeconomics; 2012 Nov; 30(11):991-1004. PubMed ID: 22950547
[TBL] [Abstract][Full Text] [Related]
27. Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Persistent Asthma in Real Clinical Practice in Spain.
Vennera Mdel C; Valero A; Uría E; Forné C; Picado C
Clin Drug Investig; 2016 Jul; 36(7):567-78. PubMed ID: 27142072
[TBL] [Abstract][Full Text] [Related]
28. Impact of asthma controller medications on clinical, economic, and patient-reported outcomes.
Tan H; Sarawate C; Singer J; Elward K; Cohen RI; Smart BA; Busk MF; Lustig J; O'Brien JD; Schatz M
Mayo Clin Proc; 2009 Aug; 84(8):675-84. PubMed ID: 19648384
[TBL] [Abstract][Full Text] [Related]
29. [Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].
; ;
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Feb; 47(2):101-119. PubMed ID: 38309959
[TBL] [Abstract][Full Text] [Related]
30. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over.
Shepherd J; Rogers G; Anderson R; Main C; Thompson-Coon J; Hartwell D; Liu Z; Loveman E; Green C; Pitt M; Stein K; Harris P; Frampton GK; Smith M; Takeda A; Price A; Welch K; Somerville M
Health Technol Assess; 2008 May; 12(19):iii-iv, 1-360. PubMed ID: 18485271
[TBL] [Abstract][Full Text] [Related]
31. Use of leukotriene receptor antagonists are associated with a similar risk of asthma exacerbations as inhaled corticosteroids.
Wu AC; Li L; Fung V; Kharbanda EO; Larkin EK; Vollmer WM; Butler MG; Miroshnik I; Rusinak D; Davis RL; Hartert T; Weiss ST; Lieu TA
J Allergy Clin Immunol Pract; 2014; 2(5):607-13. PubMed ID: 25213056
[TBL] [Abstract][Full Text] [Related]
32. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma.
Ram FS; Cates CJ; Ducharme FM
Cochrane Database Syst Rev; 2005 Jan; (1):CD003137. PubMed ID: 15674901
[TBL] [Abstract][Full Text] [Related]
33. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma.
Ducharme FM; Lasserson TJ; Cates CJ
Cochrane Database Syst Rev; 2006 Oct; (4):CD003137. PubMed ID: 17054161
[TBL] [Abstract][Full Text] [Related]
34. Addition of long-acting beta2 agonists or long-acting muscarinic antagonists versus doubling the dose of inhaled corticosteroids (ICS) in adolescents and adults with uncontrolled asthma with medium dose ICS: a systematic review and network meta-analysis.
Oba Y; Anwer S; Patel T; Maduke T; Dias S
Cochrane Database Syst Rev; 2023 Aug; 8(8):CD013797. PubMed ID: 37602534
[TBL] [Abstract][Full Text] [Related]
35. Cost-Utility Analysis of Long-Acting Beta Agonists versus Leukotriene Receptor Antagonists in Older Adults with Persistent Asthma Receiving Concomitant Inhaled Corticosteroid Therapy.
Altawalbeh SM; Thorpe JM; Thorpe CT; Smith KJ
Value Health; 2016; 19(5):537-43. PubMed ID: 27565270
[TBL] [Abstract][Full Text] [Related]
36. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.
Tzortzaki EG; Georgiou A; Kampas D; Lemessios M; Markatos M; Adamidi T; Samara K; Skoula G; Damianaki A; Schiza S; Tzanakis N; Siafakas NM
Pulm Pharmacol Ther; 2012 Feb; 25(1):77-82. PubMed ID: 22155001
[TBL] [Abstract][Full Text] [Related]
37. Clinical and economic burden of severe asthma among US patients treated with biologic therapies.
Reibman J; Tan L; Ambrose C; Chung Y; Desai P; Llanos JP; Moynihan M; Tkacz J
Ann Allergy Asthma Immunol; 2021 Sep; 127(3):318-325.e2. PubMed ID: 33775904
[TBL] [Abstract][Full Text] [Related]
38. Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma.
Carpagnano GE; Resta E; Povero M; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Barbaro MPF
Sci Rep; 2021 Mar; 11(1):5453. PubMed ID: 33750842
[TBL] [Abstract][Full Text] [Related]
39. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma.
Evans DJ; Kew KM; Anderson DE; Boyter AC
Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD011437. PubMed ID: 26196545
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States.
Sullivan PW; Li Q; Bilir SP; Dang J; Kavati A; Yang M; Rajput Y
Curr Med Res Opin; 2020 Jan; 36(1):23-32. PubMed ID: 31491337
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
